

DB Cardiology Limited
Abridged Unaudited Financial Statements
for the financial year ended 28 February 2025

DB Cardiology Limited

CONTENTS

	Page
Director's Responsibilities Statement	3
Statement of Financial Position	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 9

DB Cardiology Limited

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 28 February 2025

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable him to ensure that the financial statements and Director's Report comply with the Companies Act 2014. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

David Barton
Director

8 January 2026

DB Cardiology Limited
STATEMENT OF FINANCIAL POSITION

as at 28 February 2025

	Notes	2025 €	2024 €
Non-Current Assets			
Property, plant and equipment	6	15,637	3,573
Current Assets			
Debtors	7	293,874	297,732
Cash and cash equivalents		798,316	1,180,458
		1,092,190	1,478,190
Creditors: amounts falling due within one year	8	(82,377)	(647,886)
Net Current Assets		1,009,813	830,304
Total Assets less Current Liabilities		1,025,450	833,877
Capital and Reserves			
Called up share capital presented as equity	10	100	100
Retained earnings		1,025,350	833,777
Equity attributable to owners of the company		1,025,450	833,877

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of DB Cardiology Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 8 January 2026 and signed on its behalf by:

David Barton
Director

DB Cardiology Limited
STATEMENT OF CHANGES IN EQUITY

as at 28 February 2025

	Called up share capital €	Retained earnings €	Total €
At 1 March 2023	-	629,414	629,414
Profit for the financial year	-	204,363	204,363
At 29 February 2024	100	833,777	833,877
Profit for the financial year	-	191,573	191,573
At 28 February 2025	100	1,025,350	1,025,450

DB Cardiology Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

1. General Information

DB Cardiology Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 689259. The registered office of the company is 24 Knockrabo Drive, Mount Anville Road, Goatstown, Dublin 14 which is also the principal place of business of the company. The principal activity of the company is the provision of medical consultancy services.

Currency

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 28 February 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of services supplied by the company, exclusive value added tax.

Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	25% Straight line
----------------------------------	---	-------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

DB Cardiology Limited**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial year ended 28 February 2025

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Turnover

The whole of the company's turnover is attributable to its market in Ireland and is derived from the principal activity of the provision of medical consultancy services.

4. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of property, plant and equipment	6,703	2,152
	<u> </u>	<u> </u>

5. Employees

The average monthly number of employees, including director, during the financial year was 1, (2024 - 1).

	2025	2024
	Number	Number
Directors	1	1
	<u> </u>	<u> </u>

DB Cardiology Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

6. Property, plant and equipment	Fixtures, fittings and equipment €	Total €
Cost		
At 1 March 2024	8,609	8,609
Additions	18,767	18,767
	<hr/>	<hr/>
At 28 February 2025	27,376	27,376
	<hr/>	<hr/>
Depreciation		
At 1 March 2024	5,036	5,036
Charge for the financial year	6,703	6,703
	<hr/>	<hr/>
At 28 February 2025	11,739	11,739
	<hr/>	<hr/>
Net book value		
At 28 February 2025	15,637	15,637
	<hr/> <hr/>	<hr/> <hr/>
At 29 February 2024	3,573	3,573
	<hr/> <hr/>	<hr/> <hr/>
7. Debtors	2025 €	2024 €
Trade debtors	146,007	157,738
Other debtors	100	100
Director's current account (Note 13)	8,419	-
Taxation	139,348	139,894
	<hr/>	<hr/>
	293,874	297,732
	<hr/> <hr/>	<hr/> <hr/>
8. Creditors	2025 €	2024 €
Amounts falling due within one year		
Taxation	60,997	358,931
Director's current account (Note 13)	-	254,893
Other creditors	1	1
Accruals	21,379	34,061
	<hr/>	<hr/>
	82,377	647,886
	<hr/> <hr/>	<hr/> <hr/>
9. Taxation	2025 €	2024 €
Debtors:		
Withholding tax	139,348	139,894
	<hr/>	<hr/>
Creditors:		
Corporation tax	50,825	64,168
PAYE	10,172	294,763
	<hr/>	<hr/>
	60,997	358,931
	<hr/> <hr/>	<hr/> <hr/>

DB Cardiology Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

10. Share capital			2025 €	2024 €
Description	Number of shares	Value of units		
Authorised				
Ordinary shares of €1 each	1,000,000	€1.00 each	<u>1,000,000</u>	<u>1,000,000</u>
Allotted, called up and fully paid				
Ordinary shares of €1 each	100	€1.00 each	<u>100</u>	<u>100</u>

The director's and the secretary's interests in the shares of the company are as follows:-

Name	Class of Shares	Number Held At 28/02/25	01/03/24
David Barton	Ordinary shares of €1 each	<u>100</u>	<u>100</u>

11. Income Statement

	2025 €	2024 €
At 1 March 2024	833,777	629,414
Profit for the financial year	<u>191,573</u>	<u>204,363</u>
At 28 February 2025	<u>1,025,350</u>	<u>833,777</u>

12. Capital commitments

The company had no material capital commitments at the financial year-ended 28 February 2025.

13. Director's remuneration and transactions

	2025 €	2024 €
Director's remuneration		
Remuneration	862,655	791,252
Pension contributions	<u>43,319</u>	<u>39,996</u>
	<u>905,974</u>	<u>831,248</u>

The following amounts are repayable to the director:

	2025 €	2024 €
David Barton	<u>-</u>	<u>254,893</u>

14. Events After the End of the Reporting Period

There have been no significant events affecting the company since the financial year-end.

15. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 8 January 2026.